| アブストラクト | BACKGROUND AND AIM: We conducted a retrospective study to identify incidence rates and potential risk factors of major adverse cardiac events (MACE) in Japanese patients with ulcerative colitis (UC), as existing data are scarce, inconsistent, and provide limited representation of the real-world situation of MACE in Japan. METHODS: We utilized administrative claims data, collected between January 2013 and December 2022, from Medical Data Vision, Japan. Patients (aged >/= 20 years) diagnosed with UC within +/- 1 month of the prescription date during the study period were included in the incident cohort. Exclusions comprised patients diagnosed with UC in the first 365 days or with myocardial infarction, heart failure, stroke, or other ischemic heart diseases within 30 days pre-index. The cumulative incidence rate of MACE was calculated using the Kaplan-Meier method. Multivariate Cox regression models were used to calculate hazard ratios (HRs) for all relevant potential risk factors. RESULTS: Of 11 407 patients in the incident cohort, 91 (0.8%) experienced incident MACE. Over 120 months, the cumulative incidence rate of MACE was 2.86% (95% confidence interval [CI]: 1.89-4.32). Significant HRs (95% CI) were found for age category (>/= 65 years) (4.557 [2.786-7.452]), diabetes (1.709 [1.030-2.835]), and atrial fibrillation (AF) (2.759 [1.188-6.405]) (all p < 0.05). Patients with a history of stroke showed numerically increased risk (1.871 [0.508-6.886]) of MACE. CONCLUSIONS: The cumulative incidence rate of MACE was 2.86% over 120 months. Age, comorbidities of diabetes and AF, and history of stroke were the major risk factors for MACE in Japanese UC patients. |
|---|
| ジャーナル名 | Journal of gastroenterology and hepatology |
|---|
| Pubmed追加日 | 2024/12/12 |
|---|
| 投稿者 | Takagi, Tomohisa; Xu, Linghua; Hoshi, Masato; Arai, Shoko |
|---|
| 組織名 | Department of Molecular Gastroenterology and Hepatology, Graduate School of;Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.;Access and Value, Outcome and Evidence, Pfizer Japan Inc., Shibuya City, Tokyo,;Japan.;Specialty Care Medical Affairs, Pfizer Japan Inc., Shibuya City, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39663909/ |
|---|
